Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 252
2021 247
2022 147
2023 97
2024 42
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

702 results

Results by year

Citations

7 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. ...INTERPRETATION: In hospitalised COVID-19 pati …
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with …
Therapeutic strategies for COVID-19: progress and lessons learned.
Li G, Hilgenfeld R, Whitley R, De Clercq E. Li G, et al. Nat Rev Drug Discov. 2023 Jun;22(6):449-475. doi: 10.1038/s41573-023-00672-y. Epub 2023 Apr 19. Nat Rev Drug Discov. 2023. PMID: 37076602 Free PMC article. Review.
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or …
The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies th …
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Rosas IO, et al. N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25. N Engl J Med. 2021. PMID: 33631066 Free PMC article. Clinical Trial.
METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) …
METHODS: In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 …
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Finkel D, Green A, Mallappallil M, Faugno AJ, Zhang J, Velez JCQ, Shaefi S, Parikh CR, Charytan DM, Athavale AM, Friedman AN, Redfern RE, Short SAP, Correa S, Pokharel KK, Admon AJ, Donnelly JP, Gershengorn HB, Douin DJ, Semler MW, Hernán MA, Leaf DE; STOP-COVID Investigators. Gupta S, et al. JAMA Intern Med. 2021 Jan 1;181(1):41-51. doi: 10.1001/jamainternmed.2020.6252. JAMA Intern Med. 2021. PMID: 33080002 Free PMC article.
IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract the inflammatory cytokine release s …
IMPORTANCE: Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) …
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy.
Zanza C, Romenskaya T, Manetti AC, Franceschi F, La Russa R, Bertozzi G, Maiese A, Savioli G, Volonnino G, Longhitano Y. Zanza C, et al. Medicina (Kaunas). 2022 Jan 18;58(2):144. doi: 10.3390/medicina58020144. Medicina (Kaunas). 2022. PMID: 35208467 Free PMC article. Review.
Moreover, cytokine storm has recently emerged as a key aspect in the novel Coronavirus disease 2019, as affected patients show high levels of several key pro-inflammatory cytokines, such as IL-1, IL-2, IL-6, TNF-alpha, IFN-gamma, IP-10, GM-CSF, MCP-1, and IL-10, som …
Moreover, cytokine storm has recently emerged as a key aspect in the novel Coronavirus disease 2019, as affected patients show …
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, Malakounidou E, Zarkadi E, Tsirikos G, Georgiopoulou V, Sotiropoulou V, Koulousousa E, Chourpiliadi C, Matsioulas A, Lagadinou M, Sampsonas F, Akinosoglou K, Marangos M, Tzouvelekis A. Karampitsakos T, et al. Clin Microbiol Infect. 2023 Mar;29(3):372-378. doi: 10.1016/j.cmi.2022.10.015. Epub 2022 Oct 20. Clin Microbiol Infect. 2023. PMID: 36273769 Free PMC article.
OBJECTIVE: Randomized controlled trials comparing tocilizumab and baricitinib in patients with coronavirus disease 2019 (COVID-19) are needed. ...DISCUSSION: In the setting of this trial, baricitinib was non-inferior to tocilizumab with r …
OBJECTIVE: Randomized controlled trials comparing tocilizumab and baricitinib in patients with coronavirus disease 2019 …
Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab.
Sandhu G, Piraino ST, Piticaru J. Sandhu G, et al. Am J Ther. 2022 May-Jun 01;29(3):e275-e278. doi: 10.1097/MJT.0000000000001487. Epub 2022 Mar 4. Am J Ther. 2022. PMID: 35249968
BACKGROUND: Severe SARS-CoV-2 (COVID) pneumonia is characterized by marked inflammation. Current guidelines recommend the addition of the tocilizumab to dexamethasone in critically ill patients. ...STUDY QUESTION: Do patients …
BACKGROUND: Severe SARS-CoV-2 (COVID) pneumonia is characterized by marked inflammation. Current guidelin …
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Hermine O, et al. JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820. JAMA Intern Med. 2021. PMID: 33080017 Free PMC article. Clinical Trial.
IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). OBJECTIVE: To determine whether tocilizumab (TCZ) improves outcomes of patients hosp …
IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus …
Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.
Cardona-Pascual I, Berlana D, Martinez-Valle F, Campany-Herrero D, Montoro-Ronsano JB. Cardona-Pascual I, et al. Med Clin (Barc). 2022 Apr 8;158(7):301-307. doi: 10.1016/j.medcli.2021.03.005. Epub 2021 May 6. Med Clin (Barc). 2022. PMID: 34147248 Free PMC article.
The aim of this study was to assess the effect of tocilizumab on the outcomes of patients with COVID-19 pneumonia by using propensity-score-matching (PSM) analysis. METHODS: A retrospective observational analysis of hospitalized COVID …
The aim of this study was to assess the effect of tocilizumab on the outcomes of patients with COVID-19 pneum …
Interleukin-6: obstacles to targeting a complex cytokine in critical illness.
McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. McElvaney OJ, et al. Lancet Respir Med. 2021 Jun;9(6):643-654. doi: 10.1016/S2213-2600(21)00103-X. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872590 Free PMC article. Review.
Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cytokine as a therapeutic target. ...Here, we outline the role of IL-6 in health and disease, explain the different types of IL-6 signalling an …
Elevations in serum IL-6 concentrations in patients with severe COVID-19 have led to renewed interest in the cyt …
702 results